Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

被引：27

作者：

Funke-Chambour, Manuela ^{[1
]}

Azzola, Andrea ^{[2
]}

Adler, Dan ^{[3
]}

Barazzone-Argiroffo, Constance ^{[4
]}

Benden, Christian ^{[5
]}

Boehler, Annette ^{[6
]}

Bridevaux, Pierre-Olivier ^{[7
]}

Brutsche, Martin ^{[8
]}

Clarenbach, Christian F. ^{[5
]}

Hostettler, Katrin ^{[9
]}

Kleiner-Finger, Rebekka ^{[7
]}

Nicod, Laurent P. ^{[10
]}

Soccal, Paola M. ^{[3
]}

Tamm, Michael ^{[9
]}

Geiser, Thomas ^{[1
]}

Lazor, Romain ^{[10
]}

机构：

[1] Univ Bern, Univ Hosp Bern, Inselspital, Dept Pulm Med, Freiburgstr 8, CH-3010 Bern, Switzerland

[2] EOC Hosp Civ Lugano, Dept Internal Med, Pulmonol Serv, Lugano, Switzerland

[3] Geneva Univ Hosp, Div Pulm Dis, Dept Med Specialties, Geneva, Switzerland

[4] Geneva Univ Hosp, Pediat Pulmonol Unit, Dept Pediat, HUG, Geneva, Switzerland

[5] Univ Hosp Zurich, Div Pulmonol, Zurich, Switzerland

[6] Univ Hosp Zurich, Zurich, Switzerland

[7] Hop Valais, Dept Pulmonol, Sion, Switzerland

[8] Cantonal Hosp St Gallen, Dept Pulmonol, St Gallen, Switzerland

[9] Univ Hosp Basel, Clin Resp Med, Basel, Switzerland

[10] Univ Hosp Lausanne, Dept Pulmonol, CHUV, Lausanne, Switzerland

来源：

RESPIRATION | 2017年 / 93卷 / 05期

关键词：

Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Pulmonary fibrosis; Interstitial lung disease; RESOLUTION COMPUTED-TOMOGRAPHY; CLINICAL-PRACTICE GUIDELINE; INTERSTITIAL LUNG-DISEASE; FORCED VITAL CAPACITY; ACUTE EXACERBATIONS; THORACIC-SOCIETY; NONINVASIVE VENTILATION; N-ACETYLCYSTEINE; PIRFENIDONE; NINTEDANIB;

D O I：

10.1159/000464332

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharma-cologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF. (C) 2017 S. Karger AG, Basel

引用

页码：363 / 378

页数：16

共 99 条

[1] End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study [J].

Ahmadi, Zainab ;

Wysham, Nicholas G. ;

Lundstrom, Staffan ;

Janson, Christer ;

Currow, David C. ;

Ekstrom, Magnus .

THORAX, 2016, 71 (06) :510-516

[2] Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis [J].

Akagi, Takanori ;

Matsumoto, Takemasa ;

Harada, Taishi ;

Tanaka, Makoto ;

Kuraki, Takashige ;

Fujita, Masaki ;

Watanabe, Kentaro .

RESPIRATORY MEDICINE, 2009, 103 (08) :1209-1215

[3] Acute Exacerbations of Idiopathic Pulmonary Fibrosis [J].

Antoniou, Katerina M. ;

Wells, Athol U. .

RESPIRATION, 2013, 86 (04) :265-274

[4] Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis [J].

Bahmer, Thomas ;

Kirsten, Anne-Marie ;

Waschki, Benjamin ;

Rabe, Klaus F. ;

Magnussen, Helgo ;

Kirsten, Detlef ;

Gramm, Marco ;

Hummler, Simone ;

Brunnemer, Eva ;

Kreuter, Michael ;

Watz, Henrik .

RESPIRATION, 2016, 91 (06) :497-502

[5] The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD) - A practical approach for the pulmonologist [J].

Bahmer, Thomas ;

Romagnoli, Micaela ;

Girelli, Francesco ;

Claussen, Martin ;

Rabe, Klaus F. .

RESPIRATORY MEDICINE, 2016, 113 :80-92

[6] Management of spontaneous pneumothorax - An American College of Chest Physicians Delphi Consensus Statement [J].

Baumann, MH ;

Strange, C ;

Heffner, JE ;

Light, R ;

Kirby, TJ ;

Klein, J ;

Luketich, JD ;

Panacek, EA ;

Sahn, SA .

CHEST, 2001, 119 (02) :590-602

[7] Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case-control study [J].

Baumgartner, KB ;

Samet, JM ;

Coultas, DB ;

Stidley, CA ;

Hunt, WC ;

Colby, TV ;

Waldron, JA .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2000, 152 (04) :307-315

[8] Cigarette smoking: A risk factor for idiopathic pulmonary fibrosis [J].

Baumgartner, KB ;

Samet, JM ;

Stidley, CA ;

Colby, TV ;

Waldron, JA ;

Coultas, DB ;

Davis, GS ;

Garcia, JGN ;

Hunninghake, GW ;

Kallay, MC ;

King, TE ;

Krowka, MJ ;

Rennard, SI ;

Ryu, JH ;

Sherman, CB ;

Smith, LJ ;

Toews, G ;

Winterbauer, RH .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (01) :242-248

[9]

Behr J, 2013, Pneumologie, V67, P81, DOI 10.1055/s-0032-1326009

[10] Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial [J].

Behr, Juergen ;

Bendstrup, Elisabeth ;

Crestani, Bruno ;

Guenther, Andreas ;

Olschewski, Horst ;

Skoeld, C. Magnus ;

Wells, Athol ;

Wuyts, Wim ;

Koschel, Dirk ;

Kreuter, Michael ;

Wallaert, Benoit ;

Lin, Chin-Yu ;

Beck, Juergen ;

Albera, Carlo .

LANCET RESPIRATORY MEDICINE, 2016, 4 (06) :445-453

← 1 2 3 4 5 6 7 8 9 10 →